Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-TNFR2 monoclonal antibody BI-1910

An agonistic monoclonal antibody directed against tumor necrosis factor receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential antineoplastic activity. Upon administration, anti-TNFR2 monoclonal antibody BI-1910 targets and binds to TNFR2 expressed on the surface of CD4+ T cells, CD8+ T cells and natural killer (NK) cells in the tumor microenvironment (TME), thereby activating CD4+ T cells, CD8+ T cells and NK cells. This may enhance cytotoxic T-cell- and NK cell-mediated immune responses against tumor cells. TNFR2, a member of the TNFR family of co-stimulatory molecules, plays an important role in T-cell co-stimulation.
Synonym:anti-TNFR2 agonistic monoclonal antibody BI-1910
TNFR2 agonist antibody BI-1910
Code name:BI 1910
BI-1910
BI1910
Search NCI's Drug Dictionary